Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

June 1, 2016 updated by: Regeneron Pharmaceuticals

An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

Primary

  • Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Secondary

  • Determine the maximum tolerated intravenous dose of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
  • Determine, preliminarily, the ability of this drug to alter tumor blood flow and tumor vascular permeability in these patients.
  • Determine whether antibodies to this drug develop in these patients.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive VEGF Trap IV over 1 hour on days 1 and 15 for a total of 2 doses.

Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level.

In the absence of dose-limiting toxicity, patients with stable disease or partial or complete remission may continue to receive VEGF Trap on a separate extension protocol.

Patients are followed at weeks 1, 3, and 7 and then at 3 months.

PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10021
        • Memorial Sloan - Kettering Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 120 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed diagnosis of one of the following:

    • Non-Hodgkin's lymphoma

    • Primary or metastatic solid tumor located, by radiography, in at least one of the following sites:

      • Liver
      • Soft tissue
      • Pelvis
      • Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)

  • Relapsed or refractory (including unresectable) disease

    • Patients with solid tumors must have failed all curative chemotherapeutic regimens
    • Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
  • Not amenable to available conventional therapies AND no standard therapy exists
  • Measurable disease
  • No prior or concurrent CNS metastases (brain or leptomeningeal)
  • No primary intracranial tumor by MRI or CT scan
  • No histologically confirmed squamous cell carcinoma of the lung

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • WBC ≥ 3,500/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm^3
  • No severe or uncontrolled hematologic condition

Hepatic

  • Bilirubin ≤1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN
  • PT and PTT normal
  • INR normal
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative

Renal

  • Creatinine ≤ ULN
  • Urine protein/creatinine ratio ≤ 1
  • No severe or uncontrolled renal condition

Cardiovascular

  • No clinically significant acute electrocardiographic abnormalities
  • LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines

  • No untreated or uncontrolled hypertension

    • No blood pressure > 150/100 mm Hg (despite treatment)
  • No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at least 2 determinations [on separate days] within the past 3 months)
  • No New York Heart Association class II - IV heart disease
  • No active coronary artery disease requiring acute medical management
  • No angina requiring acute medical management
  • No congestive heart failure requiring acute medical management
  • No ventricular arrhythmia requiring acute medical management
  • No stroke or transient ischemic event within the past 6 months

  • No prior or concurrent peripheral vascular disease

    • No angiographically or ultrasonographically documented arterial or venous occlusive event
    • No symptomatic claudication
  • No symptomatic orthostatic hypotension
  • No other severe or uncontrolled cardiovascular condition

Pulmonary

  • No severe or uncontrolled pulmonary condition
  • No pulmonary embolism within the past 6 months

Immunologic

  • HIV negative
  • No severe or uncontrolled immunologic condition
  • No active current infection requiring antibiotics
  • No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap

Other

  • No severe or uncontrolled gastrointestinal or musculoskeletal condition
  • No psychiatric condition or adverse social circumstance that would preclude study participation
  • No other condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial
  • At least 3 weeks since prior immunotherapy and recovered
  • No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

Chemotherapy

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

  • No concurrent adrenal corticosteroids except low-dose replacement therapy
  • No concurrent systemic hormonal contraceptive agents

Radiotherapy

  • At least 3 weeks since prior radiotherapy and recovered

Surgery

  • At least 3 weeks since prior major or laparoscopic surgery and recovered
  • More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events

Other

  • More than 30 days since prior investigational drugs
  • No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access devices
  • No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
  • No other concurrent anticancer investigational agents
  • No other concurrent anticancer therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Regeneron Pharmaceuticals

Collaborators

National Cancer Institute (NCI)

Investigators

  • Principal Investigator: William P. Tew, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2004

Primary Completion (Actual)

May 1, 2008

Study Registration Dates

First Submitted

May 14, 2004

First Submitted That Met QC Criteria

May 18, 2004

First Posted (Estimate)

May 19, 2004

Study Record Updates

Last Update Posted (Estimate)

June 3, 2016

Last Update Submitted That Met QC Criteria

June 1, 2016

Last Verified

June 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REGENERON-VGFT-ST-0202
  • MSKCC-03137
  • CDR0000360856 (Registry Identifier: PDQ (Physician Data Query))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on ziv-aflibercept

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe